Phase I study of bisantrene in acute nonlymphoblastic leukemia.

Abstract

A phase I study of bisantrene using a daily injection for 5 days was undertaken in adult patients with relapsing acute nonlymphoblastic leukemia. Seventeen patients received 27 courses, with daily doses ranging from 75 to 250 mg/m2. Although gastrointestinal toxicity and alopecia were rare, hematological toxicity occurred in 85% of the patients. There was cholestasis unrelated to infectious events in 27% of the courses, as well as reversible renal failure in eight of 27 evaluable courses. Responses (complete + partial) were obtained in 35% +/- 10% of the patients. The recommended dose for phase II study is 200 mg/m2/day X 7.

• Authors: M Marty, C Ferme, C Gisselbrecht, H Guy, M J Clark, A Bancillon, M Boiron
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 69 Issue 6 Pg. 703-5 (Jun 1985) ISSN: 0361-5960 [Print] United States
• PMID: 4016773 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anthracenes
• Antibiotics, Antineoplastic
• bisantrene

Topics

• Acute Kidney Injury (chemically induced)
• Adult
• Anthracenes (therapeutic use, toxicity)
• Antibiotics, Antineoplastic (therapeutic use, toxicity)
• Cholestasis (chemically induced)
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Male
• Thrombocytopenia (chemically induced)